Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
Stopped 15 patients enrolled out of planned 20, terminated due to slow enrollment at end of study
Conditions
- Ewing Sarcoma
- Neuroblastoma
- Rhabdomyosarcoma
- Osteosarcoma
- CNS Tumors
Interventions
- PROCEDURE: Allogeneic HCT
- DRUG: Donor NK Cell Infusion
Sponsor
Monica Thakar